BG108072A - The use of epothilone derivatives for the treatment of refractory tumors - Google Patents

The use of epothilone derivatives for the treatment of refractory tumors

Info

Publication number: BG108072A
Authority: BG; Bulgaria
Prior art keywords: treatment; epothilone; derivatives; epothilone derivatives; refractory tumors
Prior art date: 2001-02-20

Application number

BG108072A

Other languages

Bulgarian (bg)

English (en)

Inventor

Francis Lee

Original Assignee

Bristol-Myers Squibb Company

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-02-20

Filing date

2003-08-07

Publication date

2005-04-30

2003-08-07 Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company

2005-04-30 Publication of BG108072A publication Critical patent/BG108072A/xx

Links

206010028980 Neoplasm Diseases 0.000 title abstract 3
150000003883 epothilone derivatives Chemical class 0.000 title abstract 3
238000000034 method Methods 0.000 abstract 2
241000124008 Mammalia Species 0.000 abstract 1
229940123237 Taxane Drugs 0.000 abstract 1
239000003795 chemical substances by application Substances 0.000 abstract 1
239000003937 drug carrier Substances 0.000 abstract 1
229930013356 epothilone Natural products 0.000 abstract 1
238000011275 oncology therapy Methods 0.000 abstract 1
DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 abstract 1
238000002560 therapeutic procedure Methods 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Plural Heterocyclic Compounds (AREA)

BG108072A 2001-02-20 2003-08-07 The use of epothilone derivatives for the treatment of refractory tumors BG108072A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US26985801P	2001-02-20	2001-02-20

Publications (1)

Publication Number	Publication Date
BG108072A true BG108072A (en)	2005-04-30

Family

ID=23028941

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BG108072A BG108072A (en)	2001-02-20	2003-08-07	The use of epothilone derivatives for the treatment of refractory tumors

Country Status (18)

Country	Link
US (1)	US6727276B2 (is)
EP (1)	EP1368030A1 (is)
JP (1)	JP2004522771A (is)
KR (1)	KR20040028720A (is)
CN (1)	CN1610549A (is)
BG (1)	BG108072A (is)
BR (1)	BR0207316A (is)
CA (1)	CA2438598A1 (is)
EE (1)	EE200300397A (is)
HU (1)	HUP0400041A2 (is)
IL (1)	IL157128A0 (is)
IS (1)	IS6917A (is)
MX (1)	MXPA03007423A (is)
NO (1)	NO20033682D0 (is)
PL (1)	PL363363A1 (is)
RU (1)	RU2003128312A (is)
WO (1)	WO2002066033A1 (is)
ZA (1)	ZA200306237B (is)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2273083C (en)	1996-12-03	2012-09-18	Sloan-Kettering Institute For Cancer Research	Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US20050043376A1 (en) *	1996-12-03	2005-02-24	Danishefsky Samuel J.	Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6204388B1 (en)	1996-12-03	2001-03-20	Sloan-Kettering Institute For Cancer Research	Synthesis of epothilones, intermediates thereto and analogues thereof
US6780620B1 (en) *	1998-12-23	2004-08-24	Bristol-Myers Squibb Company	Microbial transformation method for the preparation of an epothilone
US20020058286A1 (en) *	1999-02-24	2002-05-16	Danishefsky Samuel J.	Synthesis of epothilones, intermediates thereto and analogues thereof
IL157443A0 (en) *	2001-03-14	2004-03-28	Bristol Myers Squibb Co	Pharmaceutical compositions for the treatment of cancer including an epothilone analog and a chemotherapeutic agent
TW200403994A (en) *	2002-04-04	2004-03-16	Bristol Myers Squibb Co	Oral administration of EPOTHILONES
TW200400191A (en) *	2002-05-15	2004-01-01	Bristol Myers Squibb Co	Pharmaceutical compositions and methods of using C-21 modified epothilone derivatives
US7384964B2 (en) *	2002-08-23	2008-06-10	Sloan-Kettering Institute For Cancer Research	Synthesis of epothilones, intermediates thereto, analogues and uses thereof
EP2186811A1 (en) *	2002-08-23	2010-05-19	Sloan-Kettering Institute For Cancer Research	Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6921769B2 (en)	2002-08-23	2005-07-26	Sloan-Kettering Institute For Cancer Research	Synthesis of epothilones, intermediates thereto and analogues thereof
US7649006B2 (en) *	2002-08-23	2010-01-19	Sloan-Kettering Institute For Cancer Research	Synthesis of epothilones, intermediates thereto and analogues thereof
US7091193B2 (en)	2002-10-09	2006-08-15	Kosan Biosciences Incorporated	Therapeutic formulations
US20050171167A1 (en) *	2003-11-04	2005-08-04	Haby Thomas A.	Process and formulation containing epothilones and analogs thereof
US20050215604A1 (en) *	2004-03-26	2005-09-29	Kosan Biosciences, Inc.	Combination therapies with epothilones and carboplatin
EP1824458A1 (en) *	2004-11-18	2007-08-29	Bristol-Myers Squibb Company	Enteric coated bead comprising epothilone or an epothilone analog, and preparation and administration thereof
AR052142A1 (es) *	2004-11-18	2007-03-07	Bristol Myers Squibb Co	Perla recubierta enterica que comprende ixabepilona, y preparacion y administracion de la misma
US7754850B2 (en)	2005-02-11	2010-07-13	University Of Southern California	Chimeric disintegrin domain
JP4954983B2 (ja)	2005-05-18	2012-06-20	ファーマサイエンス・インコーポレイテッド	Ｂｉｒドメイン結合化合物
EP2029156A4 (en) *	2006-05-01	2010-07-21	Univ Southern California	COMBINATION THERAPY FOR CANCER TREATMENT
CN101535300B (zh)	2006-05-16	2014-05-28	埃格拉医疗公司	Iap bir域结合化合物
US8802394B2 (en)	2008-11-13	2014-08-12	Radu O. Minea	Method of expressing proteins with disulfide bridges with enhanced yields and activity
US9284350B2 (en)	2010-02-12	2016-03-15	Pharmascience Inc.	IAP BIR domain binding compounds
US20110300150A1 (en)	2010-05-18	2011-12-08	Scott Eliasof	Compositions and methods for treatment of autoimmune and other disease
CN110105368B (zh) *	2019-05-09	2022-01-07	上海大学	去氧紫杉烷类似物及其制备方法

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE4138042C2 (de)	1991-11-19	1993-10-14	Biotechnolog Forschung Gmbh	Epothilone, deren Herstellungsverfahren sowie diese Verbindungen enthaltende Mittel
JP4183099B2 (ja)	1995-11-17	2008-11-19	ゲゼルシャフト・フュア・ビオテヒノロジッシェ・フォルシュング・ミット・ベシュレンクテル・ハフツング（ゲー・ベー・エフ）	エポチロンｃおよびｄ、製造法ならびに組成物
DE19542986A1 (de)	1995-11-17	1997-05-22	Biotechnolog Forschung Gmbh	Epothilon-Derivate und deren Verwendung
DE19639456A1 (de)	1996-09-25	1998-03-26	Biotechnolog Forschung Gmbh	Epothilon-Derivate, Herstellung und Mittel
US5969145A (en) *	1996-08-30	1999-10-19	Novartis Ag	Process for the production of epothilones and intermediate products within the process
AU716610B2 (en)	1996-08-30	2000-03-02	Novartis Ag	Method for producing epothilones, and intermediate products obtained during the production process
DE19645362A1 (de)	1996-10-28	1998-04-30	Ciba Geigy Ag	Verfahren zur Herstellung von Epothilon A und B und Derivaten
DE19645361A1 (de)	1996-08-30	1998-04-30	Ciba Geigy Ag	Zwischenprodukte innerhalb der Totalsynthese von Epothilon A und B, Teil II
ES2312695T3 (es)	1996-11-18	2009-03-01	Gesellschaft Fur Biotechnologische Forschung Mbh (Gbf)	Epotilones e y f.
US6515016B2 (en)	1996-12-02	2003-02-04	Angiotech Pharmaceuticals, Inc.	Composition and methods of paclitaxel for treating psoriasis
CA2273083C (en) *	1996-12-03	2012-09-18	Sloan-Kettering Institute For Cancer Research	Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6204388B1 (en)	1996-12-03	2001-03-20	Sloan-Kettering Institute For Cancer Research	Synthesis of epothilones, intermediates thereto and analogues thereof
US6441186B1 (en)	1996-12-13	2002-08-27	The Scripps Research Institute	Epothilone analogs
US6380394B1 (en)	1996-12-13	2002-04-30	The Scripps Research Institute	Epothilone analogs
DE19701758A1 (de)	1997-01-20	1998-07-23	Wessjohann Ludgar A Dr	Epothilone-Synthesebausteine
JP2001513098A (ja)	1997-02-25	2001-08-28	ゲゼルシャフトフュアバイオテクノロギッシェフォーシュンクエムベーハー（ゲーベーエフ）	側鎖を修飾したエポチロン
DE19713970B4 (de)	1997-04-04	2006-08-31	R&D-Biopharmaceuticals Gmbh	Epothilone-Synthesebausteine II - Prenylderivate
JP4065573B2 (ja)	1997-04-18	2008-03-26	ベーリンガー・インゲルハイム・インテルナツィオナール・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング	反応媒体として圧縮二酸化炭素中における二官能性または多官能性基質の選択的オレフィンメタセシス
DE19821954A1 (de)	1997-05-15	1998-11-19	Biotechnolog Forschung Gmbh	Verfahren zur Herstellung eines Epothilon-Derivats
DE19720312A1 (de)	1997-05-15	1998-11-19	Hoechst Ag	Zubereitung mit erhöhter in vivo Verträglichkeit
DE19726627A1 (de)	1997-06-17	1998-12-24	Schering Ag	Zwischenprodukte, Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung von Epothilon
US6605599B1 (en)	1997-07-08	2003-08-12	Bristol-Myers Squibb Company	Epothilone derivatives
US6384230B1 (en)	1997-07-16	2002-05-07	Schering Aktiengesellschaft	Thiazole derivatives, method for their production and use
ES2290993T3 (es)	1997-08-09	2008-02-16	Bayer Schering Pharma Aktiengesellschaft	Nuevos derivados de epotilona, proceso para su produccion y su utilizacion farmaceutica.
US6365749B1 (en)	1997-12-04	2002-04-02	Bristol-Myers Squibb Company	Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs
TR200002299T2 (tr)	1998-02-05	2000-11-21	Novartis Ag	Epotilon kompozisyonları.
US6194181B1 (en)	1998-02-19	2001-02-27	Novartis Ag	Fermentative preparation process for and crystal forms of cytostatics
CA2322157C (en)	1998-02-25	2012-05-29	Sloan-Kettering Institute For Cancer Research	Synthesis of epothilones, intermediates thereto and analogues thereof
FR2775187B1 (fr)	1998-02-25	2003-02-21	Novartis Ag	Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
US6399638B1 (en)	1998-04-21	2002-06-04	Bristol-Myers Squibb Company	12,13-modified epothilone derivatives
WO2000000485A1 (de)	1998-06-30	2000-01-06	Schering Aktiengesellschaft	Epothilon-derivate, verfahren zu deren herstellung, zwischenprodukte und ihre pharmazeutische verwendung
WO2000031247A2 (en)	1998-11-20	2000-06-02	Kosan Biosciences, Inc.	Recombinant methods and materials for producing epothilone and epothilone derivatives
PT1140944E (pt)	1998-12-22	2004-01-30	Novartis Pharma Gmbh	Derivados de epotilona e sua utilizacao como agentes antitumorais
MXPA01008328A (es)	1999-02-18	2002-06-04	Schering Ag	Derivados de 18 -haluro epotilona, metodo para su produccion y su uso farmaceutico.
CZ301498B6 (cs) *	1999-02-22	2010-03-24	Gesellschaft Fuer Biotechnologische Forschung Mbh (Gbf)	C-21 modifikované epothilony
US6211412B1 (en)	1999-03-29	2001-04-03	The University Of Kansas	Synthesis of epothilones
PE20010116A1 (es)	1999-04-30	2001-02-15	Schering Ag	Derivados de 6-alquenil-, 6-alquinil- y 6-epoxi-epotilona, procedimientos para su preparacion

2002
- 2002-02-06 KR KR10-2003-7010872A patent/KR20040028720A/ko not_active Withdrawn
- 2002-02-06 BR BR0207316-1A patent/BR0207316A/pt not_active Application Discontinuation
- 2002-02-06 EE EEP200300397A patent/EE200300397A/xx unknown
- 2002-02-06 HU HU0400041A patent/HUP0400041A2/hu unknown
- 2002-02-06 JP JP2002565591A patent/JP2004522771A/ja active Pending
- 2002-02-06 CN CNA028052447A patent/CN1610549A/zh active Pending
- 2002-02-06 EP EP02724940A patent/EP1368030A1/en not_active Withdrawn
- 2002-02-06 PL PL02363363A patent/PL363363A1/xx not_active Application Discontinuation
- 2002-02-06 RU RU2003128312/14A patent/RU2003128312A/ru not_active Application Discontinuation
- 2002-02-06 IL IL15712802A patent/IL157128A0/xx unknown
- 2002-02-06 CA CA002438598A patent/CA2438598A1/en not_active Abandoned
- 2002-02-06 MX MXPA03007423A patent/MXPA03007423A/es unknown
- 2002-02-06 WO PCT/US2002/004247 patent/WO2002066033A1/en not_active Ceased
- 2002-02-08 US US10/071,988 patent/US6727276B2/en not_active Expired - Fee Related
2003
- 2003-08-07 BG BG108072A patent/BG108072A/xx unknown
- 2003-08-12 ZA ZA200306237A patent/ZA200306237B/en unknown
- 2003-08-18 IS IS6917A patent/IS6917A/is unknown
- 2003-08-19 NO NO20033682A patent/NO20033682D0/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
PL363363A1 (en)	2004-11-15
IL157128A0 (en)	2004-02-08
IS6917A (is)	2003-08-18
EP1368030A1 (en)	2003-12-10
CN1610549A (zh)	2005-04-27
JP2004522771A (ja)	2004-07-29
KR20040028720A (ko)	2004-04-03
WO2002066033A1 (en)	2002-08-29
EE200300397A (et)	2003-12-15
NO20033682L (no)	2003-08-19
MXPA03007423A (es)	2003-11-18
CA2438598A1 (en)	2002-08-29
HUP0400041A2 (hu)	2004-04-28
ZA200306237B (en)	2004-12-23
BR0207316A (pt)	2004-02-10
NO20033682D0 (no)	2003-08-19
RU2003128312A (ru)	2005-02-10
US20020165257A1 (en)	2002-11-07
US6727276B2 (en)	2004-04-27

Publication	Publication Date	Title
BG108072A (en)	2005-04-30	The use of epothilone derivatives for the treatment of refractory tumors
CZ309247B6 (cs)	2022-06-22	40-O-(2-hydroxyethyl)rapamycin pro použití jako jediná účinná látka při léčení solidního nádoru
ZA200305126B (en)	2004-10-01	Methods of administering epothilone analogs for the treatment of cancer.
IL244727A0 (en)	2016-05-01	Methods and preparations using immunomodulatory compounds for the treatment and management of cancer and other diseases
WO2003070163A3 (en)	2004-03-25	Prostacyclin derivatives for treating cancer
IL175714A0 (en)	2006-09-05	Quinazolinone compounds as anticancer agents
PL2484365T3 (pl)	2014-03-31	Kompozycje i sposoby leczenia chorób neowaskularnych
EP1017675A4 (en)	2001-08-22	HIGHLY LIPOPHILIC CAMPTOTHECIN DERIVATIVES
HK1041256A1 (zh)	2002-07-05	靛系双吲衍生物
TW200626138A (en)	2006-08-01	Heterocyclic derivatives and their use as therapeutic agents
AU2002321105A1 (en)	2002-12-16	Use of hepcidin for preparing a medicament for treating disorders of iron homeostasis
WO2004045593A3 (en)	2004-08-12	Combination cancer therapy with a gst-activated anticancer compound and another anticancer therapy
MXPA04004606A (es)	2004-09-10	Venenos de topoisomerasa solubilizados.
MXPA05012953A (es)	2006-02-13	Benzo[b]tiofenos 3-arilsulfanil y 3-heteroarilsulfanil sustituidos como agentes terapeuticos.
EP1458734A4 (en)	2007-12-19	ISOINDIGO, INDIGO AND INDIRUBIN DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER
WO2002070515A3 (en)	2002-12-19	Chromane derivatives, process for their preparation and their use as antitumor agents
EP1262197A3 (en)	2002-12-18	Combination treatment for sleep disorders including sleep apnea
ATE424200T1 (de)	2009-03-15	Solubilisierte topoisomerase-gift-mittel
AU2162202A (en)	2002-04-15	Antitumor therapy comprising distamycin derivatives
TW200603804A (en)	2006-02-01	Treatment with irinotecan (cpt-11) and an EGFR-inhibitor
MXPA03006412A (es)	2003-10-15	Metodos para administrar analogos de epotilona para tratamiento de cancer.
WO2003076445A3 (en)	2004-01-08	Microtubule stabilizing compounds
WO2002074756A3 (de)	2002-12-12	Urokinase-inhibitoren
TW200504051A (en)	2005-02-01	Novel acridine derivatives and their use as medicaments
DE60221104D1 (de)	2007-08-23	Substituierte diarylharnstoffe als stimulatoren der fas-vermittelten apoptose